Live-Cell Imaging Shows Proteasome Activation Improves Neuronal Survival in AD Model
AJAS · 2026 Biomedical and Health Sciences (inferred)
Overview
Alzheimer’s Disease (AD) is an incurable neurodegenerative disease (NDD) that affects ~11% of adults over the age of 65. AD, like many other NDDs, is characterized by a buildup of misfolded proteins intracellularly and extracellularly, partially due to an impaired ubiquitin-proteasome system (UPS). The proteasome is responsible for degrading misfolded proteins, and is further compromised by oxidative stress from excitotoxicity from excess glutamate levels. Compound A is a novel small molecule proteasome activator that has previously been shown to increase proteasome activity in cancer cells. Here, the effect of Compound A on proteasome activity and cell viability was examined to determine the drug’s efficacy in a cellular model of Alzheimer’s disease. Mouse hippocampal neuronal HT-22 cells were treated with Compound A, then assayed for 20S proteasome activity after 72 hours. To test the efficacy of Compound A for neuronal cell viability, untreated HT-22 cell viability was compared to cells treated with Compound A using propidium iodide staining and fluorescence microscopy (using the Satrorious IncuCyte Live-Cell Imager) over 88 hours. Results demonstrated that Compound A treatment trended toward a ~4.3-fold (p = 0.06) increase in proteasome activity after 72 hours. Additionally, Compound A outperformed 20 published proteasome activators in a comparative screen. Excitotoxicity-induced HT-22 cells treated with Compound A reduced neuronal death by 67% at 88 hours. Future tests of Compound A treatment will determine whether the drug decreases the presence of aggregating, misfolded proteins and whether Compound A has potential for therapeutic development for Alzheimer’s Disease or similar diseases.
Competition history
- AJAS 2026
Related projects
ISEF · 2026
A Multi-Target Chronopharmacotherapy for the Inhibition and Clearance of Toxic Proteins in Alzheimer's Disease
ISEF · 2015
High Throughput AD Drug Screening of Alpha-Secretase Activity Modulators as a Novel Model for Alzheimer's Disease
ISEF · 2021
The Identification and Validation of Novel Targets and Pathways of Alzheimer's Disease Through Integrated System Approaches
ISEF · 2025
Oxidative Stress-Induced Protein Aggregation in Saccharomyces cerevisiae BY4741 Exhibits Potential Pattern Relevant in Early Alzheimer's Disease
CSEF · 2018
Mitochondrial Dysfunction: A Biochemical Pathway for Early Detection of Alzheimer's Disease
ISEF · 2025
Unlocking Neuroprotection: How Chebulinic Acid Targets Protein Biomarkers and Lipid Imbalance in Alzheimer's Disease
AJAS · 2024
Development of AD in C. Elegans by Inhibiting Combinations of SGK, AKT, and PDK1
ISEF · 2014
Novel Analysis of Oxidative Stress and Inflammation on Amyloid-beta, Tau, and Motility in Transgenic C. elegans models: Targeting Potential Therapeutics for Alzheimer’s Disease
Closest projects by meaning, across every fair and year in the corpus.
Browse more like this
Source: AAAS Annual Meeting (Confex) / American Junior Academy of Science